V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10005107 | 10003190 | 1.75 | 57 | Palliative (P) | 2017-03-28 | 2017-04-10 | Capecitabine (21days) + Carboplatin | N | N | 10241457 | ECARBOX |
| 10005108 | 10003190 | 1.61 | null | Palliative (P) | 2017-05-17 | 2017-05-23 | IDELALISIB + RITUXIMAB | 2 | null | 10241457 | TEMOZOLOMIDE |
| 10005109 | 10003191 | 1.87 | 92.65 | Curative (C) | 2019-01-17 | 2019-01-18 | Sunitinib | N | null | 10242500 | PATHOS TRIAL |
| 10005110 | 10003192 | 1.74 | 105.1 | null | 2018-12-29 | 2018-12-29 | CETUXIMAB + RT | N | N | 10242855 | RALTITREXED |
| 10005111 | 10003193 | 1.7 | null | Palliative (P) | 2018-09-02 | 2018-09-29 | Cytarabine low (10to20mg/m2) IV/SC | N | N | 10243776 | MPT |
| 10005112 | 10003193 | 1.69 | 66 | Neo-adjuvant (N) | 2017-02-02 | 2017-02-04 | Gefitinib: 1 to 2 & 4 onwards | 02 | N | 10243776 | CETUXIMAB + OXALIPLATIN + MDG |
| 10005113 | 10003193 | 1.67 | 71.7 | Neo-adjuvant (N) | 2016-10-11 | 2016-10-24 | Ipilimumab | N | null | 10243776 | EVEROLIMUS |
| 10005114 | 10003194 | 1.53 | 59.3 | Curative (C) | 2016-06-02 | 2016-06-30 | Trastuzumab Subcutaneous | 02 | N | 10244555 | DA |
| 10005115 | 10003195 | 1.72 | 88.4 | Palliative (P) | 2017-03-24 | 2017-04-06 | CETUXIMAB | N | N | 10245090 | CISPLATIN + FLUOROURACIL |
| 10005116 | 10003195 | 1.64 | null | Adjuvant (A) | 2017-09-29 | 2017-10-06 | Mitomycin Intravesical | N | N | 10245090 | ERLOTINIB |
| 10005117 | 10003196 | 1.68 | 63.3 | Curative (C) | 2018-06-07 | 2018-06-16 | DABRAFENIB | null | null | 10245324 | LENALIDOMIDE |
| 10005118 | 10003197 | 1.7 | 75 | Curative (C) | 2018-03-13 | 2018-03-16 | Pazopanib | 02 | null | 10245610 | IPILIMUMAB + NIVOLUMAB |
| 10005119 | 10003198 | 1.79 | 69.7 | Palliative (P) | 2018-03-31 | 2018-04-07 | Capecitabine + Cisplatin + RT | N | Y | 10245635 | CHLORAMBUCIL + RITUXIMAB |
| 10005120 | 10003199 | 1.76 | 83.5 | Curative (C) | 2018-01-24 | 2018-01-25 | TEMOZOLOMIDE | N | N | 10245928 | AFATINIB |
| 10005121 | 10003200 | 0 | 66.8 | Curative (C) | 2017-12-14 | 2018-01-11 | Folfirinox | 02 | N | 10246569 | CISPLATIN + FLUOROURACIL + RT |
| 10005122 | 10003200 | 1.8 | null | Adjuvant (A) | 2014-05-02 | 2014-05-23 | Vemurafenib | 02 | Y | 10246569 | DOXORUBICIN EMBOLISATION |
| 10005123 | 10003201 | null | 55.7 | Palliative (P) | 2018-04-06 | 2018-05-10 | IBRUTINIB | N | N | 10247492 | DA |
| 10005124 | 10003201 | 1.73 | null | Palliative (P) | 2017-09-16 | 2017-10-10 | RUXOLITINIB | N | N | 10247492 | BLEOMYCIN |
| 10005125 | 10003202 | 1.76 | 73.6 | Neo-adjuvant (N) | 2019-05-06 | 2019-05-19 | Capecitabine (21days) + Carboplatin | N | N | 10250972 | DA |
| 10005126 | 10003203 | 1.65 | 64.5 | Disease modification (D) | 2017-06-04 | 2017-06-18 | Cyclophosphamide + Docetaxel | 02 | N | 10252278 | RCEOP |
| 10005127 | 10003204 | 1.7 | 91.2 | Palliative (P) | 2018-11-28 | 2018-12-02 | CMF IV (28 day) | 02 | N | 10252642 | STAR TRIAL |
| 10005128 | 10003205 | 1.82 | 100 | Curative (C) | 2017-08-26 | 2017-08-26 | CHLORAMBUCIL + OBINUTUZUMAB | N | N | 10252742 | CARBOPLATIN + DOCETAXEL |
| 10005129 | 10003206 | 1.66 | 75.7 | Palliative (P) | 2019-03-05 | 2019-05-24 | Erlotinib | N | N | 10253278 | VINORELBINE |
| 10005130 | 10003206 | 1.67 | 101.3 | Disease modification (D) | 2018-11-05 | 2018-11-06 | CHOP-R + CYTARABINE HIGH DOSE | N | null | 10253278 | CHLORAMBUCIL + RITUXIMAB |
| 10005131 | 10003206 | 1.6 | null | Palliative (P) | 2018-11-16 | 2018-11-17 | Ipilimumab | N | N | 10253278 | CAPECITABINE + CARBOPLATIN |
| 10005132 | 10003207 | null | 92 | Palliative (P) | 2017-04-22 | 2017-04-24 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | 10256920 | IDELALISIB + RITUXIMAB |
| 10005133 | 10003207 | null | 78 | Palliative (P) | 2015-06-13 | 2015-06-27 | DABRAFENIB | N | null | 10256920 | BENDAMUSTINE |
| 10005134 | 10003208 | null | 90.3 | Palliative (P) | 2016-06-05 | 2016-06-12 | DABRAFENIB + TRAMETINIB | 02 | N | 10258960 | ECF |
| 10005135 | 10003209 | 1.56 | 96.8 | Disease modification (D) | 2016-04-18 | 2016-05-03 | STAMPEDE TRIAL | N | null | 10259792 | CHLORAMBUCIL + OBINUTUZUMAB |
| 10005136 | 10003209 | 1.67 | null | Disease modification (D) | 2018-10-29 | 2018-11-06 | CISPLATIN + FLUOROURACIL | null | N | 10259792 | CETUXIMAB + CISPLATIN + FLUOROURACIL |
| 10005137 | 10003210 | 1.73 | 82 | Neo-adjuvant (N) | 2014-08-28 | 2014-08-29 | Carboplatin+Fluorouracil 4 or 5 day | N | N | 10261766 | AXITINIB |
| 10005138 | 10003211 | 1.67 | null | Disease modification (D) | 2016-06-27 | 2016-07-01 | Ixazomib + Lenalidomide | 02 | null | 10261840 | CAPECITABINE + CARBOPLATIN |
| 10005139 | 10003212 | 1.72 | 60 | Curative (C) | 2017-09-23 | 2017-09-25 | IBRUTINIB | N | N | 10262453 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 10005140 | 10003212 | 1.75 | null | Disease modification (D) | 2018-09-29 | 2018-10-23 | Sorafenib | 2 | N | 10262453 | ATEZOLIZUMAB |
| 10005141 | 10003212 | 1.7 | 92 | Palliative (P) | 2015-08-04 | 2015-08-19 | AML18 PILOT TRIAL | 02 | N | 10262453 | IPILIMUMAB |
| 10005142 | 10003212 | 1.69 | 82 | Palliative (P) | 2014-09-27 | 2014-09-30 | Bortezomib + MELPHALAN | N | N | 10262453 | BUSULPHAN |
| 10005143 | 10003212 | 1.56 | 64.1 | Disease modification (D) | 2019-03-04 | 2019-03-04 | TCH (21 day Trastuzumab) Loading | N | N | 10262453 | TRASTUZUMAB |
| 10005144 | 10003212 | null | 78 | null | 2018-06-29 | 2018-06-29 | BLEOMYCIN | N | N | 10262453 | INCA TRIAL |
| 10005145 | 10003212 | 1.77 | 76.9 | Palliative (P) | 2018-03-24 | 2018-03-24 | VINCRISTINE | N | N | 10262453 | HCX |
| 10005146 | 10003213 | 0 | 80.5 | Palliative (P) | 2019-07-10 | 2019-07-24 | Capecitabine (21days) + Carboplatin | N | Y | 10266634 | CETUXIMAB + IRINOTECAN + MDG |
| 10005147 | 10003214 | 1.74 | 90.8 | Palliative (P) | 2019-04-06 | 2019-04-15 | GEFITINIB | 2 | N | 10266734 | CHLORAMBUCIL + RITUXIMAB |
| 10005148 | 10003215 | 1.72 | 76.4 | Palliative (P) | 2018-08-21 | 2018-09-09 | ETOPOSIDE | 02 | N | 10268176 | ECF |
| 10005149 | 10003216 | 1.74 | 67.2 | null | 2017-01-25 | 2017-02-13 | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 2 | N | 10268360 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 10005150 | 10003217 | 1.88 | 116.2 | null | 2016-06-17 | 2016-06-17 | IBRUTINIB | 02 | N | 10269488 | ERLOTINIB |
| 10005151 | 10003218 | 1.64 | 67.9 | Curative (C) | 2017-12-02 | 2017-12-14 | DABRAFENIB + TRAMETINIB | 02 | N | 10269868 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10005152 | 10003219 | 1.94 | 0 | Adjuvant (A) | 2018-05-24 | 2018-06-04 | Pazopanib | N | N | 10270465 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 10005153 | 10003220 | 0 | 65.8 | Curative (C) | 2018-04-21 | 2018-04-23 | Pemetrexed | 2 | N | 10271024 | IRINOTECAN |
| 10005154 | 10003221 | 1.73 | 68 | Curative (C) | 2018-11-03 | 2018-11-04 | MPV (cycle 1-4) | N | N | 10271252 | RUXOLITINIB |
| 10005155 | 10003222 | 1.66 | null | Curative (C) | 2015-10-30 | 2015-11-13 | NIVOLUMAB | N | Y | 10272123 | CETUXIMAB + IRINOTECAN + MDG |
| 10005156 | 10003223 | 1.65 | 97.3 | Neo-adjuvant (N) | null | 2019-05-25 | IDELALISIB + RITUXIMAB | Y | null | 10272906 | CYTARABINE HD + METHOTREXATE HD |